BRPI0509191A - polimorfo cristalino, composição, métodos de preparar forma a polimórfica de acetato de bazedoxifeno, de tratar um mamìfero possuindo uma doença ou sìndrome associada com deficiência de estrogênio ou excesso de estrogênio, e com proliferação ou desenvolvimento anormal de tecidos endometriais, cáncer de mama em um mamìfero, e uma mulher pós-menopausal para um ou vários distúrbios vasomotores, de abaixar colesterol em um mamìfero, e de inibir perda óssea em um mamìfero, e, forma a polimorfa cristalina de acetato de bazedoxifeno - Google Patents
polimorfo cristalino, composição, métodos de preparar forma a polimórfica de acetato de bazedoxifeno, de tratar um mamìfero possuindo uma doença ou sìndrome associada com deficiência de estrogênio ou excesso de estrogênio, e com proliferação ou desenvolvimento anormal de tecidos endometriais, cáncer de mama em um mamìfero, e uma mulher pós-menopausal para um ou vários distúrbios vasomotores, de abaixar colesterol em um mamìfero, e de inibir perda óssea em um mamìfero, e, forma a polimorfa cristalina de acetato de bazedoxifenoInfo
- Publication number
- BRPI0509191A BRPI0509191A BRPI0509191-8A BRPI0509191A BRPI0509191A BR PI0509191 A BRPI0509191 A BR PI0509191A BR PI0509191 A BRPI0509191 A BR PI0509191A BR PI0509191 A BRPI0509191 A BR PI0509191A
- Authority
- BR
- Brazil
- Prior art keywords
- mammal
- crystalline polymorph
- bazedoxifene acetate
- estrogen
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
POLIMORFO CRISTALINO, COMPOSIçãO, MéTODOS DE PREPARAR FORMA A POLIMóRFICA DE ACETATO DE BAZEDOXIFENO, DE TRATAR UM MAMìFERO POSSUINDO UMA DOENçA OU SìNDROME ASSOCIADA COM DEFICIêNCIA DE ESTROGêNIO OU EXCESSO DE ESTROGêNIO, E COM PROLIFERAçãO OU DESENVOLVIMENTO ANORMAL DE TECIDOS ENDOMETRIAIS, CáNCER DE MAMA EM UM MAMìFERO, E UMA MULHER PóS-MENOPAUSAL PARA UM OU VáRIOS DISTúRBIOS VASOMOTORES, DE ABAIXAR COLESTEROL EM UM MAMìFERO, E DE INIBIR PERDA óSSEA EM UM MAMìFERO, E, FORMA A POLIMORFA CRISTALINA DE ACETATO DE BAZEDOXIFENO. A presente invenção refere-se a um polimorfo cristalino de acetato de bazedoxifeno, às composições contendo o mesmo, às suas preparações, e aos seus usos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56058204P | 2004-04-07 | 2004-04-07 | |
US66017805P | 2005-03-10 | 2005-03-10 | |
PCT/US2005/011724 WO2005100316A1 (en) | 2004-04-07 | 2005-04-06 | Crystalline polymorph of a bazedoxifene acetate |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0509191A true BRPI0509191A (pt) | 2007-09-25 |
Family
ID=34966308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0509191-8A BRPI0509191A (pt) | 2004-04-07 | 2005-04-06 | polimorfo cristalino, composição, métodos de preparar forma a polimórfica de acetato de bazedoxifeno, de tratar um mamìfero possuindo uma doença ou sìndrome associada com deficiência de estrogênio ou excesso de estrogênio, e com proliferação ou desenvolvimento anormal de tecidos endometriais, cáncer de mama em um mamìfero, e uma mulher pós-menopausal para um ou vários distúrbios vasomotores, de abaixar colesterol em um mamìfero, e de inibir perda óssea em um mamìfero, e, forma a polimorfa cristalina de acetato de bazedoxifeno |
Country Status (18)
Country | Link |
---|---|
US (1) | US7683051B2 (pt) |
EP (1) | EP1732890A1 (pt) |
JP (2) | JP2007532560A (pt) |
KR (1) | KR20060135866A (pt) |
AR (1) | AR048527A1 (pt) |
AU (1) | AU2005233133A1 (pt) |
BR (1) | BRPI0509191A (pt) |
CA (1) | CA2561010A1 (pt) |
CR (1) | CR8615A (pt) |
EC (1) | ECSP066911A (pt) |
IL (1) | IL178236A0 (pt) |
NO (1) | NO20065052L (pt) |
PA (1) | PA8629101A1 (pt) |
PE (1) | PE20060676A1 (pt) |
RU (1) | RU2006132180A (pt) |
SG (1) | SG151331A1 (pt) |
TW (1) | TWI346105B (pt) |
WO (1) | WO2005100316A1 (pt) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7683052B2 (en) * | 2004-04-07 | 2010-03-23 | Wyeth | Crystalline polymorph of bazedoxifene acetate |
US7683051B2 (en) | 2004-04-07 | 2010-03-23 | Wyeth | Crystalline polymorph of bazedoxifene acetate |
US8538393B1 (en) | 2004-09-21 | 2013-09-17 | Advanced Ground Information Systems, Inc. | Method to provide ad hoc and password protected digital and voice networks |
US10645562B2 (en) | 2004-09-21 | 2020-05-05 | Agis Software Development Llc | Method to provide ad hoc and password protected digital and voice networks |
JP2008545012A (ja) * | 2005-06-29 | 2008-12-11 | ワイス | 結合型エストロゲンおよびバゼドキシフェンの医薬処方 |
PE20070425A1 (es) * | 2005-08-24 | 2007-07-02 | Wyeth Corp | Composicion farmaceutica que comprende acido 1-[4-(2-azepan-1-il-etoxi)-bencil]-2-(4-hidroxifenil)-3-metil-1h-indol-5-ol acetico (acetato de bazedoxifeno) como modulador selectivo del receptor de estrogenos |
PE20090100A1 (es) * | 2007-03-30 | 2009-02-26 | Wyeth Corp | Metodos de separacion y deteccion de acetato de bacedoxifeno en composiciones farmaceuticas |
CZ302358B6 (cs) * | 2007-07-25 | 2011-03-30 | Zentiva, A. S. | Nové soli bazedoxifenu |
WO2009102778A1 (en) * | 2008-02-11 | 2009-08-20 | Wyeth | Amorphous polymorph of bazedoxifene acetate |
US20100016582A1 (en) * | 2008-02-11 | 2010-01-21 | Wyeth | Methods of converting polymorphic form b of bazedoxifene acetate to polymorphic form a of bazedoxifene acetate |
WO2009102773A1 (en) * | 2008-02-11 | 2009-08-20 | Wyeth | Methods of preparing polymorphic form a of bazedoxifene acetate |
ITMI20091109A1 (it) * | 2009-06-23 | 2010-12-24 | Wyeth Corp | Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione |
CA2775599A1 (en) | 2009-10-27 | 2011-05-12 | Wyeth Llc | Bazedoxifene formulations with antioxidants |
US8154175B2 (en) * | 2009-12-16 | 2012-04-10 | Hamilton Sundstrand Corporation | Sensing device |
WO2012007453A1 (en) | 2010-07-14 | 2012-01-19 | Sandoz Ag | Crystalline compound of 1-[4-(2-azepan-1-ylethoxy)benzyl]-2-(4-hydroxyphenyl)-3-methyl-1h-indol-5-ol |
EP2407467A1 (de) | 2010-07-14 | 2012-01-18 | Sandoz Ag | Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure |
US9212172B2 (en) | 2010-09-14 | 2015-12-15 | Dr. Reddy's Laboratories Limited | Preparation of crystalline bazedoxifene and its salts |
EP2471770A1 (en) * | 2010-12-28 | 2012-07-04 | Sandoz Ag | Method of preparing polymorphic pure form A of bazedoxifene acetate |
WO2013182170A1 (en) | 2012-06-07 | 2013-12-12 | Zentiva, K. S. | Enhancement of dissolution rate from pharmaceutical composition comprising bazedoxifene acetate |
WO2013182169A1 (en) | 2012-06-07 | 2013-12-12 | Zentiva, K. S. | Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate |
JP2016518449A (ja) | 2013-05-15 | 2016-06-23 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | インドール製剤を調製するためのプロセスおよび中間体 |
CN111060619B (zh) * | 2019-12-18 | 2022-11-18 | 北京鑫开元医药科技有限公司 | 一种醋酸巴多昔芬杂质的检测方法 |
US11246874B1 (en) | 2021-04-20 | 2022-02-15 | Oxygen Biotech LLC | Treatment of COVID-19 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5880137A (en) | 1996-04-19 | 1999-03-09 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
US5780497A (en) | 1996-04-19 | 1998-07-14 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
ES2162198T3 (es) | 1996-04-19 | 2001-12-16 | American Home Prod | Agentes estrogenos. |
US5998402A (en) * | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
TW397821B (en) | 1996-04-19 | 2000-07-11 | American Home Produits Corp | 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof |
US6005102A (en) | 1997-10-15 | 1999-12-21 | American Home Products Corporation | Aryloxy-alkyl-dialkylamines |
KR100669836B1 (ko) | 1997-10-15 | 2007-01-18 | 와이어쓰 | 신규한 아릴옥시-알킬-디알킬아민 및 이의 제조 방법 |
US6479535B1 (en) | 1998-05-15 | 2002-11-12 | Wyeth | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
AR029538A1 (es) | 2000-07-06 | 2003-07-02 | Wyeth Corp | Composiciones farmaceuticas de agentes estrogenicos |
EP1336602A1 (en) | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases |
RU2005101635A (ru) | 2002-06-25 | 2005-08-10 | Уайт (Us) | Применение производных тиооксиндола в терапии гормонозависимых состояний |
US7683051B2 (en) | 2004-04-07 | 2010-03-23 | Wyeth | Crystalline polymorph of bazedoxifene acetate |
-
2005
- 2005-04-06 US US11/100,983 patent/US7683051B2/en active Active
- 2005-04-06 AR ARP050101367A patent/AR048527A1/es unknown
- 2005-04-06 EP EP05738044A patent/EP1732890A1/en not_active Withdrawn
- 2005-04-06 KR KR1020067020649A patent/KR20060135866A/ko not_active Application Discontinuation
- 2005-04-06 RU RU2006132180/04A patent/RU2006132180A/ru not_active Application Discontinuation
- 2005-04-06 SG SG200902227-8A patent/SG151331A1/en unknown
- 2005-04-06 CA CA002561010A patent/CA2561010A1/en not_active Abandoned
- 2005-04-06 BR BRPI0509191-8A patent/BRPI0509191A/pt not_active IP Right Cessation
- 2005-04-06 JP JP2007507487A patent/JP2007532560A/ja not_active Abandoned
- 2005-04-06 PA PA20058629101A patent/PA8629101A1/es unknown
- 2005-04-06 AU AU2005233133A patent/AU2005233133A1/en not_active Withdrawn
- 2005-04-06 TW TW094110850A patent/TWI346105B/zh active
- 2005-04-06 PE PE2005000386A patent/PE20060676A1/es not_active Application Discontinuation
- 2005-04-06 WO PCT/US2005/011724 patent/WO2005100316A1/en active Application Filing
-
2006
- 2006-09-12 CR CR8615A patent/CR8615A/es not_active Application Discontinuation
- 2006-09-21 IL IL178236A patent/IL178236A0/en unknown
- 2006-10-06 EC EC2006006911A patent/ECSP066911A/es unknown
- 2006-11-02 NO NO20065052A patent/NO20065052L/no not_active Application Discontinuation
-
2008
- 2008-06-30 JP JP2008171135A patent/JP2009035535A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US7683051B2 (en) | 2010-03-23 |
PA8629101A1 (es) | 2005-11-25 |
JP2007532560A (ja) | 2007-11-15 |
AU2005233133A1 (en) | 2005-10-27 |
PE20060676A1 (es) | 2006-07-24 |
IL178236A0 (en) | 2006-12-31 |
NO20065052L (no) | 2006-11-06 |
ECSP066911A (es) | 2006-12-20 |
TWI346105B (en) | 2011-08-01 |
EP1732890A1 (en) | 2006-12-20 |
CA2561010A1 (en) | 2005-10-27 |
CR8615A (es) | 2007-06-06 |
TW200606149A (en) | 2006-02-16 |
WO2005100316A1 (en) | 2005-10-27 |
KR20060135866A (ko) | 2006-12-29 |
AR048527A1 (es) | 2006-05-03 |
SG151331A1 (en) | 2009-04-30 |
RU2006132180A (ru) | 2008-05-20 |
JP2009035535A (ja) | 2009-02-19 |
US20050227965A1 (en) | 2005-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0509191A (pt) | polimorfo cristalino, composição, métodos de preparar forma a polimórfica de acetato de bazedoxifeno, de tratar um mamìfero possuindo uma doença ou sìndrome associada com deficiência de estrogênio ou excesso de estrogênio, e com proliferação ou desenvolvimento anormal de tecidos endometriais, cáncer de mama em um mamìfero, e uma mulher pós-menopausal para um ou vários distúrbios vasomotores, de abaixar colesterol em um mamìfero, e de inibir perda óssea em um mamìfero, e, forma a polimorfa cristalina de acetato de bazedoxifeno | |
BRPI0509257A (pt) | polimorfo cristalino de acetato de bazedoxifeno, composição, processo para preparar um polimorfo e para aumentar a proporção de acetato de bazedoxifeno forma b em uma composição, métodos de tratar um mamìfero, cáncer de mama e uma mulher em pós-menopausa para um ou mais distúrbios vasomotores, de abaixar colesterol e de inibir perda óssea em um mamìfero e uso de um polimorfo | |
MX2010004244A (es) | Derivados de imidazo [i,2-a]-piridina utiles como inhibidores de cinasa tipo activina (alk). | |
WO2005077968A3 (en) | 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity | |
BRPI0816064B8 (pt) | composto inibidor da atividade de proteína tirosina quinase, seu uso, e composição farmacêutica | |
BRPI0517224A (pt) | composto, composição farmecêutica, e, usos de um composto e de uma composição | |
JP2007532548A5 (pt) | ||
SG170033A1 (en) | Octahydro-pyrrolo[3,4-b] pyrrole derivatives and their use as histamine-3 receptor ligands | |
UY32251A (es) | Compuestos quimicos | |
BR9905788A (pt) | Derivados de 2-(2-oxo-etilideno)-imidazolidin-4-ona e composições e métodos para a inibição do crescimento de célula anormal que compreendem os referidos derivados | |
WO2009151598A8 (en) | Diazacarbazoles and methods of use | |
TN2010000040A1 (en) | 2-3-7-substituted imidazo - [1-2b] pyridazines for treatment of alk 4 or alk 5 mediated diseases | |
WO2009091898A3 (en) | 6-and 7-amino isoquinoline compounds and methods for making and using the same | |
SI1896421T1 (sl) | Benzocikloheptapiridini kot inhibitorji receptorjev tirozin kinaze met | |
WO2007112043A3 (en) | Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin | |
ECSP066730A (es) | Compuestos y procedimientos para uso | |
NO20084927L (no) | Fosfoinositid-3-kinaseinhibitorforbindelser og farmasoytiske sammensetninger inneholdende dem | |
WO2010058032A3 (en) | Substituted pyrimidines for the treatment of diseases such as cancer | |
NZ588711A (en) | C-17 homologated oleanolic acid derivatives for treating cancer | |
WO2007024717A3 (en) | Agents for preventing and treating disorders involving modulation of the ryr receptors | |
WO2008008310A3 (en) | Tyrosine kinase inhibitors | |
MX2008002061A (es) | Derivados de tiazolil piperidina utiles como moduladores del receptor h3. | |
WO2010033543A3 (en) | Substituted benzamides as cannabinoid receptor ligands | |
TNSN08370A1 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
WO2010028338A3 (en) | Novel compounds as cannabinoid receptor ligands |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |